Hollister Incorporated sustainability score: 42/100

Hollister Incorporated published a 2024 Sustainability Report (its second annual report) and a 2023 report, both disclosing Scope 1 and Scope 2 emissions at a high level. The 2024 report headline states a '13% reduction in Scope 1 and Scope 2 emissions compared to our 2022 baseline,' but no absolute tonnage figures are accessible in publicly indexed excerpts. The UK subsidiary Carbon Reduction Plan (2024) confirms GHG Protocol methodology is used, with 2022 as the baseline year, but the parent-level absolute figures are not publicly disclosed in an accessible format. Without verified absolute tonnage figures, and with no third-party assurance cited, this scores at the mid-range of the self-calculated/partially disclosed tier. A medical device manufacturer at this scale (estimated Scope 1+2 likely in the 20,000–60,000 tonne range based on industry benchmarks for similar-sized manufacturers) is not negligible, so the lack of publicly accessible absolute figures prevents a higher score.

Hollister Incorporated has identified Scope 3 categories (purchased goods and services, upstream transportation and distribution, end-of-life) and set a 25% reduction target for these categories by 2030. However, no absolute Scope 3 tonnage figures are publicly available in indexed sources. As a medical device manufacturer using plastics, adhesives, and packaging with global supply chains spanning Ireland, India, Denmark, Lithuania, the Netherlands, and the US, supply chain emissions are likely the dominant portion of total footprint. The company shows awareness of supply chain impact and has begun target-setting, but no quantified baseline for Scope 3 is publicly confirmed, and no supplier engagement programme results are documented. This warrants a score of 3: above basic awareness but below the threshold of quantified categories with methodology.

The 2024 Sustainability Report confirms a 13% absolute reduction in Scope 1 and Scope 2 emissions versus the 2022 baseline — this is framed as an absolute reduction, not an intensity improvement. The 2023 report also cited reducing Scope 1 and 2 emissions globally. This constitutes two consecutive years of reported absolute reductions, which is directionally positive. However, no independent verification of the trajectory is available, Scope 3 trajectory is not reported, and no multi-year data table with absolute figures is accessible to confirm consistency. The score reflects evidenced year-on-year absolute reduction direction (warranting at least 5–6) but is held back from 6 due to absence of verified absolute tonnage data and no confirmed Scope 3 trajectory.

Hollister Incorporated has invested in on-site solar installations at its Kaunas, Lithuania and Bawal, India manufacturing facilities (Enercore confirms a 500 kWp rooftop solar system at the Bawal site). The 2023 report notes 'strategic investments and renewable energy sourcing' at global manufacturing sites. ISO 14001 certification for all European and India manufacturing/distribution sites was completed by end of 2024. However, no overall renewable energy percentage for global operations is publicly disclosed, no RE100 membership or PPA for the full portfolio is documented, and it is unknown whether the solar installations represent a material share of total electricity consumption. This evidence supports a score of 4 (green/renewable energy at specific sites, efficiency investments), but cannot reach 6 without a disclosed percentage and confirmed transition plan.

No TNFD disclosure, no formal biodiversity policy, and no deforestation commitment is found for Hollister Incorporated. As a medical device manufacturer producing single-use products from plastics, adhesives, and textiles, there is meaningful nature risk in the supply chain (synthetic material extraction, packaging). No evidence of nature risk assessment, habitat impact evaluation, or supply chain nature due diligence was identified in any publicly available source. The company has ISO 14001 certification at its European and India sites, which includes some environmental management requirements, but this is a process certification rather than a nature/biodiversity outcome assessment. Score of 2 reflects basic awareness-level at best, with no documented mitigation of key nature risks beyond general environmental management systems.

Hollister Incorporated has a target of 80% waste diversion rate by 2027 (stated in 2023 Sustainability Report) and reported progress toward this goal. The company also reports progress on product design to reduce environmental impact. Manufacturing of single-use medical products (ostomy pouches, catheters, wound dressings) involves plastics and packaging with significant material throughput. The 2024 report references resource stewardship as a commitment but does not provide verified waste diversion percentages achieved to date. The 80% target is specific and time-bound, which is positive, and the company is making progress, but no verified current diversion rate or circular economy programme specifics are accessible. Score of 4 reflects active waste minimisation target with some evidence of progress but lacking verified metrics.

No water consumption data, water reduction targets, or water stewardship programme details are publicly accessible for Hollister Incorporated in any indexed sustainability report excerpt. ISO 14001 certification at manufacturing sites implies some environmental management of water as part of the system, but no quantified water footprint or discharge data is evident. As a medical device manufacturer, water is used in manufacturing processes (e.g., catheter production, wound dressing processing), but Hollister's operations are not in the highest-risk water-intensive sectors. Score of 2 reflects the absence of publicly accessible water data from a company of this size with manufacturing operations — the company likely knows its water consumption via operational data but has not disclosed it publicly.

Hollister Incorporated has set specific, time-bound targets: 42% reduction in Scope 1 and 2 by 2030 (2022 baseline); 25% reduction in Scope 3 (selected categories) by 2030; 90% reduction across all scopes by 2050 with net-zero goal via carbon offsets; UK subsidiary targets 90% reduction by 2045. These are absolute targets, which is the appropriate measure. However, no SBTi commitment or validation has been found — a check of the SBTi dashboard and related sources does not confirm Hollister Incorporated (medical devices) as committed or validated. The 2050 net-zero pathway explicitly mentions 'through the implementation of carbon offsets,' which raises offset-reliance concerns for the long-term target. The near-term 2030 targets are reduction-first and specific. Score of 4 reflects self-set specific absolute targets without SBTi validation, and modest concern about offset reliance in the long-term pathway.

Hollister Incorporated has published two annual sustainability reports (2022, 2023, 2024), demonstrating a developing public disclosure programme. The 2024 report confirms a dedicated ESG department including an ESG Director, Analyst, and VP of Operations as ESG Executive Champion, plus cross-functional ESG Council and working groups. A Carbon Reduction Plan is publicly available for the UK subsidiary (2024), meeting SECR requirements. No third-party assurance of emissions data is identified; no TCFD or CSRD-aligned disclosure is found; no executive compensation linkage to sustainability targets is documented. Board-level oversight is implied through the ESG Council structure but not explicitly confirmed. Score of 5 reflects a genuine dedicated sustainability role and team, public reporting, and GHG Protocol methodology — but no external assurance, no mandatory framework disclosure, and no compensation linkage.

No regulatory actions, fines, greenwashing rulings, NGO reports, or credible journalistic investigations have been identified targeting Hollister Incorporated (the medical devices company). No lobbying activity against climate policy has been found; InfluenceMap does not list this private medical device company. No structural enablement of fossil-sector commerce applies. The company's core business (single-use medical devices for ostomy, continence, and critical care) is not associated with environmental controversy. Starting score of 8, with a minor deduction of 1 for the fact that the company's 2050 net-zero pathway explicitly relies on carbon offsets ('through the implementation of carbon offsets') without any detail on offset quality or credible CDR strategy, which is a mild greenwashing indicator for the long-term claim. Score: 7.